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Abstract.
Background: Clinical diagnosis of parkinsonian syndromes like Parkinson’s disease (PD), corticobasal degeneration (CBD)
and progressive supranuclear palsy (PSP) is hampered by overlapping symptomatology and lack of diagnostic biomarkers,
and definitive diagnosis is only possible post-mortem.
Objective: Since impaired protein degradation plays an important role in many neurodegenerative disorders, we hypothesized
that profiles of select lysosomal network proteins in cerebrospinal fluid could be differentially expressed in these parkinsonian
syndromes.
Methods: Cerebrospinal fluid samples were collected from PD patients (n = 18), clinically diagnosed 4-repeat tauopathy
patients; corticobasal syndrome (CBS) (n = 3) and PSP (n = 8); and pathologically diagnosed PSP (n = 8) and CBD patients
(n = 7). Each patient set was compared to its appropriate control group consisting of age and gender matched individuals.
Select lysosomal network protein levels were detected via Western blotting. Factor analysis was used to test the diagnostic
sensitivity, specificity and accuracy of the select lysosomal network protein expression profiles.
Results: PD, CBD and PSP were markedly different in their cerebrospinal fluid lysosomal network protein profiles.
Lysosomal-associated membrane proteins 1 and 2 were significantly decreased in PD; early endosomal antigen 1 was
decreased and lysozyme increased in PSP; and lysosomal-associated membrane proteins 1 and 2, microtubule-associated
protein 1 light chain 3 and lysozyme were increased in CBD. A panel of lysosomal-associated membrane protein 2, lysozyme
and microtubule-associated protein 1 light chain discriminated between controls, PD and 4-repeat tauopathies.
Conclusions: This study offers proof of concept that select lysosomal network proteins are differentially expressed in
cerebrospinal fluid of Parkinson’s disease, corticobasal syndrome and progressive supranuclear palsy. Lysosomal network
protein analysis could be further developed as a diagnostic fluid biomarker in parkinsonian syndromes.
Keywords: Biomarkers, CSF, parkinson’s disease (PD), corticobasal degeneration (CBD), progressive supranuclear palsy
(PSP)
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INTRODUCTION
There is a compelling need to develop diagnos-
tic biomarkers for Parkinson’s disease (PD) and
atypical parkinsonian syndromes (APS), including
corticobasal degeneration (CBD) and progressive
supranuclear palsy (PSP). Due to their overlapping
clinical manifestations, the diagnosis of these con-
ditions can often be challenging, especially during
their early clinical stages. Despite having similar
clinical presentations, PD and the APS have dif-
ferent associated neuropathological features [1–4],
which suggest that the underlying neurodegenerative
mechanisms are also distinct, and their neurochem-
ical footprints could be discerned through biofluid
analysis for diagnostic purposes. Recent studies have
explored the diagnostic and prognostic value of
cerebrospinal fluid analysis of a number of pro-
teins typically associated with neurodegenerative
conditions, including amyloid-1-42 (A1-42), tau,
alpha synuclein (-synuclein) and neurofilament
light chain (NFL) in Parkisonian syndromes [5].
Whereas studies for individual proteins in specific
parkinsonian syndromes have sometimes been incon-
clusive [6], a panel approach, where a combination of
several biomarkers is analyzed, has proven to reach
higher accuracy and specificity [7]. Given that, pro-
tein misfolding, the key neuropathological changes
in parkinsonian syndromes has been observed many
years before the manifestation of clinical signs, some
of the earliest pathogenic changes are hypothesized
to involve mechanisms affecting protein autophagy,
degradation and clearance [8–10]. Some of the earli-
est changes in Alzheimer’s disease (AD) have been
described in connection to the lysosomal network,
an interconnected vesicular network of endosomes,
lysosomes and autophagosomes, that is crucial for
protein homeostasis [11]. We recently observed select
CSF lysosomal network protein increases in a large
group of AD patients, including early endosomal
antigen 1 (EEA1), lysosomal-associated membrane
proteins 1 and 2 (LAMP-1, LAMP-2), lysozyme and
microtubule-associated protein 1 light chain 3 (LC3)
[12, 13]. The goal of this exploratory pilot study was
to provide proof-of-principle that lysosomal network
protein analysis reveals neurochemical differences in
parkinsonian syndromes that could be further devel-
oped into diagnostic fluid biomarkers. We measured
CSF levels of the select lysosomal network proteins
EEA1, LAMP-1, LAMP-2, LC3 and lysozyme in
PD, CBD and PSP patients, and determined whether
their expression profiles are different compared to
controls. A subset of analyses included CSF from
pathologically confirmed CBD and PSP patients.
Markedly different protein profiles were observed in
PD and APS samples, compared to controls.
MATERIALS AND METHODS
Study population
CSF set 1: PD
CSF samples from PD patients (n = 18) who met
the criteria for PD as defined by The United King-
dom PD Society Brain Bank [14], but not autopsy
confirmed, were obtained from the Karolinska hos-
pital. The patients were matched in age and gender,
with controls suffering from benign neurological con-
ditions, such as tension headache and unclassified
sensory disturbances (n = 18). The characteristics of
the patients included in CSF set 1 are presented in
Table 1.
Table 1
Cerebrospinal fluid (CSF) study demographics of Parkinson’s Disease (PD) and controls (C) (CSF set 1), clinically confirmed 4-repeat
tauopathy (CBS and PSP) patients and C (CSF set 2), clinically and pathologically confirmed CBD and PSP patients and C (CSF set 3).
Sample collection and CSF measurements for sets 1 and 2 were performed at Karolinska University Hospital and at UCSF for set 3. Data
are presented as the mean and (range). There was no overlap between control samples used in the different sets.
Age (years) Gender Disease duration Levodopa equivalent
(M:F) (years) dose (LED)
CSF set 1
PD (n = 18) 61 (39–80) 15 : 3 4 (1–14) 114 (0–2012)
C (n = 18) 62 (46–83) 14 : 4 n/a n/a
CSF set 2
Clinically confirmed 4-repeat tauopathy (n = 11) 71 (63–81) 7 : 4 3 (1–6) 143 (0–764)
C (n = 11) 64 (54–73) 6 : 5 n/a n/a
CSF set 3
Pathologically confirmed CBD (n = 7) 64 (61–70) 4 : 3 6 (5–8) 0
Pathologically confirmed PSP (n = 8) 69 (55–88) 2 : 6 10 (4–17) 150 (0–600)
C (n = 10) 59 (52–68) 4 : 6 n/a n/a
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CSF set 2: Clinically diagnosed 4-repeat
tauopathies
4-repeat tauopathy CSF samples, from clinically
diagnosed CBS (n = 3) and PSP patients (n = 8),
were obtained at the Karolinska hospital. Patients
with PSP were clinically diagnosed with possible
or probable PSP according to the National Insti-
tute of Neurological Disorders and Stroke-Society
for Progressive Supranuclear Palsy (NINDS-SPSP)
criteria [15]. Briefly, these include: 1) a gradually
progressive disorder with onset at the age of 40
years or later and 2) vertical supranuclear gaze palsy
and prominent postural instability within the first
year of disease onset. Patients with CBS were diag-
nosed according to the Armstrong criteria [16]. The
following features were required for a clinical diag-
nosis of CBS: 1) a slowly progressive course, 2)
asymmetric limb or axial rigidity, present without
reinforcement, 3) aphasia, visuospatial impairment
or neglect, or apraxia, and 4) dystonia, myoclonus,
cortical sensory loss, or alien limb phenomenon.
The patients were matched in age and gender, with
controls (n = 11) suffering from benign neurological
conditions, such as tension headache and unclas-
sified sensory disturbances. The characteristics of
the patients included in CSF set 2 are presented in
Table 1.
CSF set 3: Pathologically confirmed CBD
and PSP
CSF samples from clinically diagnosed and patho-
logically confirmed PSP (n = 8) and CBD (n = 7)
patients, were obtained from the University of
California, San Francisco Memory and Aging Cen-
ter. Patients with PSP were clinically diagnosed
with possible or probable PSP according to the
National Institute of Neurological Disorders and
Stroke-Society for Progressive Supranuclear Palsy
(NINDS-SPSP) criteria [15]. Patients with CBD
were diagnosed according to the Armstrong criteria
[16]. Pathological confirmation of the disease was
performed on postmortem brains according to the
previously described method [17]. The patients were
matched in age and gender, with cognitively normal
healthy elderly controls (n = 10) with no neurolog-
ical complaints. The characteristics of the patients
included in CSF set 3 are presented in Table 1.
CSF sampling
A standardized lumbar puncture (LP) procedure
was performed fasting and sitting up, in accordance
with the Alzheimer’s Disease Neuroimaging Initia-
tive (ADNI) recommended protocol. Samples were
collected into sterile polypropylene tubes, the first
2 mL were discarded and between 12 and 15 mL CSF
from the first portion was collected and gently mixed
in order to minimize the gradient influence and cen-
trifuged in the original tube at 4000RPM for 10 min
at +4◦C. CSF samples were divided into aliquots put
on dry ice before storing at –80◦C until assayed.
Blood-contaminated samples were excluded, and
time between sample collection and freezing was
maximum 1 hour. The clinically confirmed CBS and
PSP CSF samples were collected during workup for
parkinsonism. The pathologically confirmed CBD
and PSP CSF samples were collected from live
patients between 3.5 and 8 years after symptoms
appeared, with an average disease duration of 6 and
10 years respectively.
Ethical statement
All the investigations of the patients and the
analyses of their CSF were approved by the ethic
committees of the respective institutions. Informed
consent was obtained from the subjects.
Protein quantitation by Western immunoblotting
The CSF protein analysis via Western blotting has
been described elsewhere [12], with the following
change, blotting onto a 0.45m nitrocellulose mem-
brane in transfer buffer (Tris-Base 25 mM, Glycine
192 mM, methanol 20%) for 1 h at 100 V and +4◦C.
The following antibodies were used: LAMP-1 and
LAMP-2 (9835-01 and 9840-01, Southern Biotech,
Burmingham, AL, USA), LC3 (NB600-1384, Novus
Biologicals, Littleton, CO, USA), EEA1 (E4156,
Sigma Aldrich, St. Louis, MO, USA), lysozyme
and horseradish peroxidase-conjugated antibodies
(A0099, P0448 and P0447, Dako, Glostrup, Den-
mark). The films were scanned and the immunoblots
were quantified using the Image J program (avail-
able at http://rsbweb.nih.gov/ij/). All antibodies were
confirmed to recognize their epitope via Western
blot analysis of SH-SY5Y cell lysates, as well as
overexpressing cell lines. Furthermore, most of the
antibodies are highly specific and display only a
single band of the CSF samples. Due to individual
differences in protein concentrations in CSF, 20L
of CSF were loaded per sample and equal sample
loading was verified by Ponceau S (Sigma Aldrich)
staining of total protein in each lane on the mem-
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branes (representative blot in Fig. 1 C). A standard
CSF sample from one healthy control individual was
loaded on each gel for normalization between the
gels. Each gel was loaded with both control and
patient samples and the samples were randomly dis-
tributed on the gels, and each sample set required
multiple gels to fit all samples. Any difference in
blot intensity was removed by subtracting the blot
background for each sample separately.
Statistical analyses
Data were visually explored with histogram and
box plots for normality and presence of outliers.
Additional tests for normality were conducted with
the Shapiro-Wilk test. All data were normally dis-
Fig. 1. The lysosomal network proteins LAMP-1 and LAMP-2
are downregulated in the CSF of PD patients. A) Representative
samples from one Western blot of CSF from controls (C) and
Parkinson’s disease (PD) patients analyzed for the lysosomal net-
work proteins EEA1, LAMP-1, LAMP-2, LC3 and lysozyme. B)
Mean densitometric quantification of the scanned Western blots
from C (n = 18) and PD (n = 18) patients. The protein levels are
normalized to a standard CSF sample loaded on each gel. C) Equal
sample loading was verified by Ponceau S staining of total protein
in each lane on the membranes. The bars represent the mean ± SD,
∗p < 0.05.
tributed and further data analysis proceeded with
parametric tests. Mean densitometric Western blot
values for each protein were compared with inde-
pendent samples bidirectional Student’s t test. In set
2, data for CBS and PSP were combined into a single
group of 4-repeat tauopathy. Factor analysis was used
to test the sensitivity, specificity and accuracy of the
select lysosomal network protein expression profiles
to classify patients into the correct diagnostic group.
Individual Western blot densitometric values for each
lysosomal protein were used as independent vari-
able predictors. Diagnoses (i.e. control, PD, CBD and
PSP) were established as dependent grouping vari-
ables. Means and variance for control groups in the
three different sets were similar. Thus, for factor anal-
yses, data from sets 1, 2, and 3 were pooled, resulting
in 39 controls, 18 PD, 10 CBD and 16 PSP cases.
Statistical significance was defined for p-values of
less than 0.05 (∗), 0.01 (∗∗) and 0.001 (∗∗∗). Statisti-
cal analyses were performed using GraphPad Prism
version 5.0 for Windows (GraphPad Software, San
Diego, CA, USA) and SPSS version 23 (SPSS/IBM,
Chicago, IL).
RESULTS
Decreased levels of the lysosomal network
proteins LAMP-1 and LAMP-2 in PD CSF
We investigated the presence and levels of the lyso-
somal network proteins EEA1, LAMP-1, LAMP-2,
LC3 and lysozyme in control and PD CSF (Table 1,
CSF set 1) using Western blot analysis. Mature,
functional LAMP-1 and LAMP-2 proteins are exten-
sively glycosylated and run as spread out bands
with a molecular weight between 100–150 kDa on
Western blots. LAMP-1 and LAMP-2 levels were
significantly decreased in the PD samples as com-
pared with the control CSF samples (Fig. 1A and
B). There was a 23% decrease in LAMP-1 levels,
and a 30% decrease in LAMP-2 levels in PD CSF.
Equal sample loading was confirmed via Ponceau
S staining of total protein in each lane (Fig. 1C),
and all proteins were detected in human SH-SY5Y
neuroblastoma cell lysates, confirming the ability of
the antibodies to recognize the epitopes (data not
shown). EEA1, LC3 and lysozyme were present at
detectable levels in the CSF, but no significant dif-
ferences were observed between controls and PD
patients. The complete Western blots containing all
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CSF samples are demonstrated in Supplementary
Figure 1A.
Increased levels of lysosomal network protein
LC3 in clinically diagnosed 4-repeat tauopathy
CSF
Next, we investigated the levels of the lysosomal
network proteins in CSF from clinically diagnosed
4-repeat tauopathy patients, consisting of CBS and
PSP patients. Contrary to the findings in the PD
CSF samples, the levels of LAMP-1 and LAMP-2
were unchanged, while LC3 levels were significantly
increased in 4-repeat taupathy patients, correspond-
ing to a value 92% higher, compared with control
CSF samples (Fig. 2A and B). EEA1 and lysozyme
were present at detectable levels in the CSF, but
no significant difference was observed between
CSF samples from control and 4-repeat tauopathy
patients. The complete western blots containing all
CSF samples are demonstrated in Supplementary
Figure 1B.
Fig. 2. The lysosomal network protein LC3 is upregulated in the
CSF of clinically diagnosed 4-repeat tauopathy patients. A) Repre-
sentative samples from one Western blot of CSF from controls (C)
and clinically diagnosed 4-repeat tauopathy patients (CBS/PSP),
analyzed for the lysosomal network proteins EEA1, LAMP-1,
LAMP-2, LC3 and lysozyme B) Mean densitometric quantification
of the scanned Western blots from C (n = 11), clinically diagnosed
4-repeat tauopathy patients (CBS, n = 6 and PSP, n = 5). The pro-
tein levels are normalized to a standard CSF sample loaded on each
gel. C) Equal sample loading was verified by Ponceau S staining
of total protein in each lane on the membranes. The bars represent
the mean ± SD, ∗∗∗p < 0.001.
Different CSF level profiles of lysosomal network
proteins EEA-1, LAMP-1, LAMP-2, LC3 and
lysozyme in pathologically confirmed CBD and
PSP CSF
To confirm our findings, and to further explore the
differences in lysosomal network protein expression
profiles between PD, CBS and PSP, we investi-
gated the levels of the lysosomal network proteins
in CSF from clinically diagnosed CBD and PSP
patients where the diagnosis had been pathologically
confirmed post-mortem. LAMP-1, LAMP-2, LC3
and lysozyme levels were significantly increased in
pathologically confirmed CBD compared with con-
trol samples (Fig. 3A and B); LAMP-1 by 66%,
LAMP-2 and LC3 by 280% and lysozyme by 456%.
A different pattern emerged in the pathologically
confirmed PSP patients, where the EEA1 level was
significantly decreased by 29% and the lysozyme
level was significantly increased by 211% in PSP
patient CSF compared with control samples (Fig. 3C
and D). The complete western blots containing all
CSF samples are demonstrated in Supplementary
Figure 1C.
Patterns of lysosomal network proteins showed
high diagnostic accuracy
Analyses combining data from the three sets was
used to test the diagnostic accuracy of the lysoso-
mal network protein expression levels. The patterns
of LAMP-1 and LAMP-2 expression were useful for
separating controls from patients with PD (X2 = 10.2,
p = 0.006) with sensitivity of 94.9%, specificity of
44.4% and accuracy of 78.9%. The effect size was
0.17. A profile including LAMP-2, lysozyme and
LC-3 was useful at discriminating controls from
CBD with a sensitivity of 100%, specificity of 60%
and accuracy of 91.8% (X2 = 32.1, p < 0.001). The
effect size was 0.50. The expression of lysozyme
was different in controls and PSP patients. Lysozyme
expression identified PSP patients with a sensitiv-
ity of 97.4%, specificity of 31.3% and accuracy of
78.2% (X2 = 12.1, p < 0.001). The effect size was
0.20. The expression patterns of LAMP-1, LAMP-2,
lysozyme and LC-3 were useful at discriminat-
ing patients with PD from patients with 4-repeat
tauopathies (CBD and PSP combined) with a sensi-
tivity of 77.8%, specificity of 73.1% and accuracy
of 75% (X2 = 10.4, p = 0.03). The effect size was
0.23. A model testing simultaneous discrimination
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between controls, PD and 4-repeat tauopathies
showed that a composite of LAMP-2, lysozyme and
LC-3 had a sensitivity of 92.3% but low specificity
for both PD (5.6%) and 4-repeat tauopathies (38.5%)
(X2 = 32.3 p < .001). The accuracy of this compos-
ite model was 56.6%, with an effect size of 0.28
(Fig. 4).
Fig. 3. The lysosomal network proteins LAMP-1, LAMP-2, LC3
and lysozyme are upregulated in the CSF of pathologically con-
firmed CBD patients, whilst EEA1 is decreased and lysozyme is
upregulated in the CSF of pathologically confirmed PSP patients.
A) Representative samples from one Western blot of CSF from
controls (C) and pathologically confirmed corticobasal degenera-
tion (CBD) patients analyzed for the lysosomal network proteins
EEA1, LAMP-1, LAMP-2, LC3 and lysozyme. B) Mean densito-
metric quantification of the scanned Western blots from C (n = 10)
and pathologically confirmed CBD (n = 7) patients. C) Represen-
tative Western blots of CSF from controls (C) and pathologically
confirmed progressive supranuclear palsy patients (PSP) analyzed
for the lysosomal network proteins EEA1, LAMP-1, LAMP-2,
LC3 and lysozyme. D) Densitometric quantification of the scanned
Western blots from C (n = 10) and pathologically confirmed PSP
patients (n = 8). The protein levels are normalized to a standard
CSF sample loaded on each gel. E and F) Equal sample loading
was verified by Ponceau S staining of total protein in each lane
on the membranes in A and C respectively. The bars represent the
mean ± SD, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
DISCUSSION
We have discovered that parkinsonian syndromes
display different patterns of CSF select lysosomal
network proteins, compared to their appropriate con-
trols. The lysosomal proteins LAMP-1 and LAMP-2
were significantly decreased in PD compared with
control; LC3 was increased in clinically diag-
nosed 4-repeat tauopathy patients (CBS and PSP)
compared with controls; pathologically diagnosed
CBD patients had significantly increased LAMP-
1, LAMP-2, LC3 and lysozyme levels compared
with controls; whilst pathologically diagnosed PSP
patients had significantly decreased EEA1 level and
increased lysozyme levels compared with controls.
A pool factorial analysis confirmed that combined
patterns of lysosomal patterns are sensitive at dis-
criminating controls from the different parkinsonian
diseases. These results support that the lysosomal
protein network is activated in parkinsonian syn-
dromes. Furthermore, a combination of LAMP-1,
LAMP-2, LC3 and lysozyme levels was able to
Fig. 4. Patterns of lysosomal network protein expression showed
differences between control subjects, patients with Parkinson’s dis-
ease and 4-repeat tauopathies (CBD and PSP combined). Function
1 (canonical coefficients: lysozyme 1.4, LAMP-2 -0.15 and LC3 -
0.39) showed a higher segregation of 4-repeat tauopathies (4RTau)
patients. In turn, function 2 (canonical coefficients: LAMP-2 1.7,
lysozyme –0.8 and LC3 –1.4, respectively) showed discrimina-
tion of PD patients. Control subjects featured comparatively lower
LC3 with variable lysozyme and LC3. Conversely, PD featured
low LC3 and lysozyme, whereas 4-repeat tauopathies showed high
lysozyme score with variable LAMP-2 and LC3.
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distinguish patients with PD, from patients with
4-repeat tauopathies. It can thus be hypothesized
that profiles of lysosomal network proteins could
be different among parkinsonian diseases and could
have value as biomarkers useful in the differen-
tial diagnosis of PD, CBD and PSP. These data
are consistent with previous results from AD CSF
samples, where no general increase of lysosomal
network proteins was observed, but a select subset
of lysosomal proteins was changed [12]. Based on
these data showing differential expression profiles of
select CSF lysosomal network proteins, further val-
idating studies that also address their specificity in
parkinsonian syndromes should be pursued. Whether
other parkinsonian syndromes with different associ-
ated pathology, such as multiple system atrophy, or
other non-related parkinsonian conditions with pre-
dominant tau pathology, such as behavioral variant
frontotemporal dementia, share some of the observed
CSF lysosomal protein changes should be also further
explored.
Some of the earliest abnormalities observed in
AD and PD are connected to malfunctioning pro-
tein clearance in the lysosomal network [11, 18,
19]. Our data indicate that it is highly likely that
changes to lysosomal network proteins are involved
in the pathogenesis of CBD and PSP, in one or more
of the lysosomal network compartments; lysosomes,
autophagosomes or endosomes. The pathologies of
AD, PD, PSP and CBD have in common the accumu-
lation of misfolded and aggregation-prone proteins;
A,-synuclein, and tau, which are not degraded effi-
ciently but instead may negatively affect degradation
pathways, such as the lysosomal network [20]. It has
been previously described that levels of LAMP-2 are
decreased early in the disease progression in the PD
brain [10, 21]. in particular, the lysosomal membrane
protein isoform LAMP-2A is believed to be primar-
ily involved in PD-related neurodegeneration, since
the levels of the isoforms LAMP-2B and LAMP-
2C are unchanged [22] and LAMP-2A is known
to be involved in chaperone mediated autophagy.
The decreased level of LAMP-2 correlates with a
decreased level and activity of glucocerebrosidase
and high levels of -synuclein in PD [21]. Our study
demonstrates decreased levels of LAMP-2 in CSF
from PD patients, which may reflect the levels of glu-
cocerebrosidase and-synuclein in the PD brain. The
levels of the lysosomal membrane protein LAMP-
1 are not altered in substantia nigra pars compacta
or amygdala in the PD brain [10, 23], however,
we detected a decreased level of LAMP-1 in PD
CSF which might indicate that other brain regions
and different cellular subtypes could be implicated
in PD-related neurodegeneration. Overexpressing -
synuclein in a microglia cell line shows, among other
things, decreased LAMP-1 levels [24]. In the present
study, CBD cases showed increased CSF LAMP-1
and 2 levels, mirroring what is seen in AD [12].
We found that the level of the lysosomal glycoside
hydrolase and innate immunity protein lysozyme was
increased in CBD but unchanged in PD and PSP.
The increase of lysozyme in CBD could reflect an
astrocytic response towards the tau pathology seen
in astrocytes in this disorder [4]. LC3 is involved in
formation of the autophagosome and earlier reports
show increased levels of autophagic vesicles con-
taining LC3 in PD brains as well as mice and cell
models [9]. LC3 and impaired autophagy have previ-
ously been reported in a cellular model of CBD and
PSP [8], as well as in a mouse model for tauopathies
[25]. We could not detect any differences in LC3 lev-
els in CSF from PD or pathologically diagnosed PSP
patients, but the protein was found at higher levels
in CSF in pathologically confirmed CBD patients.
Why the previously reported increased LC3 levels
in the PD brain is not mirrored in the CSF could be
explained by that LC3 was reported to be sequestered
in Lewy bodies in PD [10, 23], and that Lewy bod-
ies are also detected in some PSP patients [26]. The
endosomal protein EEA1, which is involved in fusion
and delivery of endosomal cargo, was significantly
decreased in CSF from PSP cases, but to our knowl-
edge there are no prior studies on EEA1 in PD,
CBD or PSP.
The difference in results between the clinically
diagnosed CBS and PSP samples versus the patho-
logically diagnosed CBD and PSP samples could
be caused by the propensity of clinically diagnosed
patients to be misdiagnosed [27], highlighting the
need for reliable biomarkers, but could also indicate
that the levels of certain proteins changes during the
disease progression, like prior reports that sAPP
levels decreases longitudinally in APS patients [7].
It is noteworthy that the lysosomal marker profile
of pathologically-confirmed CBD patients resembles
that of the one previously reported for AD patients
[12, 13], more than PD patients, even though not
identical, where CBD and AD patients have increased
levels of LAMP-1, LAMP-2, lysozyme and LC3. This
finding indicates that there may be overlapping patho-
physiological changes in lysosomal function between
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these disorders and that therapies directed towards
optimizing lysosomal functions in AD may turn out
to be beneficial also in CBD. A recent study inves-
tigating the diagnostic power of combining the nine
CSF proteins T-Tau, NFL, monocyte chemoattractant
protein-1, YKL-40, sAPP, sAPP, A1-42, P-Tau
and-synuclein to distinguish between e.g. PD, APS,
AD and DLB gave promising results [7]. To com-
bine the levels and patterns of these proteins with
the lysosomal network proteins, LAMP-1, LAMP-2,
lysozyme, LC3 and EEA1 might boost the diagnostic
accuracy of this diagnostic panel.
There are several limitations to this study. The
number of analyzed cases is small, which likely
resulted in underestimation of specificity and low
accuracy. This in turn compromises the external
validity of the findings. The predictive value of the
current findings is contingent upon their replication
in larger patient sets. Samples were obtained from
different centers, which possibly contributed to case
heterogeneity, thus affecting sensitivity estimates.
Also, disease duration at the time of CSF sam-
pling significantly varied between patient diagnoses
and analyte levels could be significantly affected by
the disease stage. The cross-sectional nature of this
analysis presents a reduced dimension of analyte
expression and further longitudinal studies will be
needed to examine the consistency of the observed
changes and the prognostic utility of the profiles.
A strength of this study is the use of age-matched
controls in each recruitment center. This may over-
come potential bias related to sample processing.
In addition, no differences were observed in control
values across patient sets. This study also included
more than one diagnostic group, which explores the
specificity of the diagnostic tests. Results observed
in clinically diagnosed APS cases had a replication
in pathologically-diagnosed counterparts. The use of
pathologically confirmed cases aids in the specificity
of findings and strengthens the findings in light of our
previous report on AD patients.
In summary; this study provides proof of principle
that the levels and patterns of the select lysosomal
network proteins LAMP-1, LAMP-2, lysozyme, LC3
and EEA1 differ between PD, CBD and PSP CSF as
compared to their appropriate controls. These pro-
teins have the potential as tools in investigating the
disease mechanisms for AD, parkinsonian disorders
and other neurodegenerative conditions featuring
abnormal protein degradation and aggregation, as
potential biomarkers to distinguish between the dis-
eases; and perhaps even as future targets for novel
treatments. Further validation studies on the role of
lysosomal network protein expression profiles are
indicated.
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